ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis

Brain Research

Volumn 1607, Issue , 2015, Pages 1-14

  Jablonski, Michael ^a   Miller, David S ^b   Pasinelli, Piera ^a   Trotti, Davide ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Amyotrophic; Blood brain barrier; Drug efflux transporters; Lateral; Neurodegeneration; Pharmacoresistance; Sclerosis

Indexed keywords

ABC TRANSPORTER; RILUZOLE; XENOBIOTIC AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BLOOD SPINAL CORD BARRIER; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; ENDOTHELIUM CELL; GLIA; HUMAN; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SURVIVAL; TARGET CELL; ANIMAL; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY;

ANIMALIA;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE; HUMANS;

EID: 84926042496     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.08.060     Document Type: Review

References (137)

1. G. Acsadi, R.A. Anguelov, H. Yang, G. Toth, R. Thomas, A. Jani, Y. Wang, E. Ianakova, S. Mohammad, R.A. Lewis, and M.E. Shy Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy Hum. Gene Ther. 13 2002 1047 1059
2. S. Agarwal, A.M.S. Hartz, W.F. Elmquist, and B. Bauer Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up Curr. Pharm. Des. 17 2011 2793 2802
3. S.P. Aggarwal, L. Zinman, E. Simpson, J. Mckinley, K.E. Jackson, H. Pinto, R.A. Conwit, and D.A. Schoenfeld Clinical trial testing lithium in ALS terminates early for futility Lancet Neurol. 9 2010 481 488 10.1016/S1474-4422(10)70068-5
4. A. Al-Chalabi, A. Jones, C. Troakes, A. King, S. Al-Sarraj, and L.H. van den Berg The genetics and neuropathology of amyotrophic lateral sclerosis Acta Neuropathol. 124 2012 339 352 10.1007/s00401-012-1022-4
5. O.A. Andreassen, A. Dedeoglu, P. Klivenyi, M.F. Beal, and A.I. Bush N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis Neuroreport 11 2000 2491 2493
6. O.A. Andreassen, B.G. Jenkins, A. Dedeoglu, K.L. Ferrante, M.B. Bogdanov, R. Kaddurah-Daouk, and M.F. Beal Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation J. Neurochem. 77 2001 383 390
7. J.P. Bankstahl, K. Hoffmann, K. Bethmann, and W. Loscher Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain Neuropharmacology 54 2008 1006 1016
8. A.L. Bartels, R. Kortekaas, J. Bart, A.T.M. Willemsen, O.L. de Klerk, J.J. de Vries, J.C.H. van Oostrom, and K.L. Leenders Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration Neurobiol. Aging 30 2009 1818 1824 10.1016/j.neurobiolaging.2008.02.002
9. B. Bauer, X. Yang, A.M.S. Hartz, E.R. Olson, R. Zhao, J.C. Kalvass, G.M. Pollack, and D.S. Miller In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein Mol. Pharmacol. 70 2006 1212 1219 10.1124/mol.106.023796.inhibitors
10. B. Bauer, A.M.S. Hartz, and D.S. Miller Tumor necrosis factor-alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier Mol. Pharmacol. 71 2007 667 675 10.1124/mol.106.029512.with
11. B. Bauer, A.M.S. Hartz, A. Pekcec, K. Toellner, D.S. Miller, and H. Potschka Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling Mol. Pharmacol. 73 2008 1444 1453 10.1124/mol.107.041210.show
12. M. Bauer, M. Zeitlinger, R. Karch, P. Matzneller, J. Stanek, W. Jäger, M. Böhmdorfer, W. Wadsak, M. Mitterhauser, J.P. Bankstahl, W. Löscher, M. Koepp, C. Kuntner, M. Müller, and O. Langer Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data Clin. Pharmacol. Ther. 91 2012 227 233 10.1038/clpt.2011.217
13. M. Benatar Lost in translation: treatment trials in the SOD1 mouse and in human ALS Neurobiol. Dis. 26 2007 1 13 10.1016/j.nbd.2006.12.015
14. R. Bendayan, P.T. Ronaldson, D. Gingras, and M. Bendayan In situ localization of P-glycoprotein (ABCB1) in human and rat brain J. Histochem. Cytochem. 54 2006 1159 1167 10.1369/jhc.5A6870.2006
15. T. Bordet, B. Buisson, M. Michaud, C. Drouot, P. Galea, P. Delaage, N.P. Akentieva, A.S. Evers, D.F. Covey, and M.A. Ostuni Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis J. Pharmacol. Exp. Ther. 322 2007 709 720
16. W. Boston-howes, E.O. Williams, A. Bogush, M. Scolere, P. Pasinelli, and D. Trotti Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis Exp. Neurol. 213 2008 229 237 10.1016/j.expneurol.2008.06.010
17. C. Brandt, K. Bethmann, A.M. Gastens, and W. Löscher The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy Neurobiol. Dis. 24 2006 202 211 10.1016/j.nbd.2006.06.014
18. R.E. Cannon, J.C. Peart, B.T. Hawkins, C.R. Campos, and D.S. Miller Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain Proc. Natl. Acad. Sci. USA 109 2012 15930 15935 10.1073/pnas.1203534109
19. T.A. Cartwright, C.R. Campos, R.E. Cannon, and D.S. Miller Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers J. Cereb. Blood Flow Metab. 33 2013 381 388 10.1038/jcbfm.2012.174
20. G.N.Y. Chan, M.T. Hoque, C.L. Cummins, and R. Bendayan Regulation of P-glycoprotein by orphan nuclear receptors in human brain microvessel endothelial cells J. Neurochem. 118 2011 163 175 10.1111/j.1471-4159.2011.07288.x
21. J.R. Cirrito, R. Deane, A.M. Fagan, M.L. Spinner, M. Parsadanian, M.B. Finn, H. Jiang, J.L. Prior, A. Sagare, K.R. Bales, S.M. Paul, B.V. Zlokovic, D. Piwnica-worms, and D.M. Holtzman P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model J. Clin. Investig. 115 2005 3285 3290 10.1172/JCI25247.mdr1a
22. H.C. Cooray, C.G. Blackmore, L. Maskell, and M.A. Barrand Localisation of breast cancer resistance protein in microvessel endothelium of human brain Neuroreport 13 2002 2059 2063
23. C. Crochemore, M. Virgili, B. Bonamassa, D. Canistro, E. Pena-Altamira, M. Paolini, and A. Contestabile Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis Muscle Nerve 39 2009 548 552
24. J.P. Crow, N.Y. Calingasan, J. Chen, J.L. Hill, and M.F. Beal Manganese porphyrin given at symptom onset markedly extends survival of ALS mice Ann. Neurol. 58 2005 258 265
25. M.E. Cudkowicz, J.M. Shefner, D.A. Schoenfeld, R.H. Brown Jr., H. Johnson, M. Qureshi, M. Jacobs, J.D. Rothstein, S.H. Appel, and R.M. Pascuzzi A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis Neurology 61 2003 456 464
26. M.E. Cudkowicz, P.L. Andres, S.A. Macdonald, R.S. Bedlack, R. Choudry, R.H. Brown Jr., H. Zhang, D.A. Schoenfeld, J. Shefner, and S. Matson Phase 2 study of sodium phenylbutyrate in ALS Amyotroph. Lateral Scler. 10 2009 99 106
27. M. DeJesus-Hernandez, I.R. Mackenzie, B.F. Boeve, A.L. Boxer, M. Baker, N.J. Rutherford, A.M. Nicholson, N.A. Finch, H. Flynn, J. Adamson, N. Kouri, A. Wojtas, P. Sengdy, G.-Y.R. Hsiung, A. Karydas, W.W. Seeley, K.A. Josephs, G. Coppola, D.H. Geschwind, Z.K. Wszolek, H. Feldman, D.S. Knopman, R.C. Petersen, B.L. Miller, D.W. Dickson, K.B. Boylan, N.R. Graff-Radford, and R. Rademakers Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS Neuron 72 2011 245 256 10.1016/j.neuron.2011.09.011
28. T. de Paulis ONO-2506 Ono. Curr. Opin. Investig. Drugs 4 2003 863 867
29. H.-X. Deng, W. Chen, S.-T. Hong, K.M. Boycott, G.H. Gorrie, N. Siddique, Y. Yang, F. Fecto, Y. Shi, H. Zhai, H. Jiang, M. Hirano, E. Rampersaud, G.H. Jansen, S. Donkervoort, E.H. Bigio, B.R. Brooks, K. Ajroud, R.L. Sufit, J.L. Haines, E. Mugnaini, M.A. Pericak-Vance, and T. Siddique Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia Nature 477 2011 211 215 10.1038/nature10353
30. C. Desnuelle, M. Dib, C. Garrel, and A. Favier A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2 2001 9 18
31. D.B. Drachman, K. Frank, M. Dykes-Hoberg, P. Teismann, G. Almer, S. Przedborski, and J.D. Rothstein Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS Ann. Neurol. 52 2002 771 778
32. J.N. Dulin, M.L. Moore, and R.J. Grill The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord J. Neurotrauma 30 2013 211 226
33. L. Dupuis, R. Dengler, M.T. Heneka, T. Meyer, S. Zierz, J. Kassubek, W. Fischer, F. Steiner, E. Lindauer, M. Otto, J. Dreyhaupt, T. Grehl, A. Hermann, A.S. Winkler, U. Bogdahn, R. Benecke, B. Schrank, C. Wessig, J. Grosskreutz, and A.C. Ludolph A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis PLoS One 7 2012 e37885 10.1371/journal.pone.0037885
34. H.L. Feng, Y. Leng, C.H. Ma, J. Zhang, M. Ren, and D.M. Chuang Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model Neuroscience 155 2008 567 572
35. L. Ferraiuolo, J. Kirby, A.J. Grierson, M. Sendtner, and P.J. Shaw Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis Nat. Rev. Neurol. 7 2011 616 630 10.1038/nrneurol.2011.152
36. F. Fornai, P. Longone, L. Cafaro, O. Kastsiuchenka, M. Ferrucci, M.L. Manca, G. Lazzeri, A. Spalloni, N. Bellio, P. Lenzi, N. Modugno, G. Siciliano, C. Isidoro, L. Murri, S. Ruggieri, and A. Paparelli Lithium delays progression of amyotrophic lateral sclerosis Proc. Natl. Acad. Sci. USA 105 2008 2052 2057 10.1073/pnas.0708022105
37. S. Garbuzova-Davis, M.C.O. Rodrigues, D.G. Hernandez-Ontiveros, M.K. Louis, A.E. Willing, C.V. Borlongan, and P.R. Sanberg Amyotrophic lateral sclerosis: a neurovascular disease Brain Res. 1398 2011 113 125 10.1016/j.brainres.2011.04.049
38. G.D. Ghadge, B.S. Slusher, A. Bodner, M.D. Canto, K. Wozniak, A.G. Thomas, C. Rojas, T. Tsukamoto, P. Majer, and R.J. Miller Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models Proc. Natl. Acad. Sci. USA 100 2003 9554 9559
39. P.H. Gordon, D.H. Moore, D.F. Gelinas, C. Qualls, M.E. Meister, J. Werner, M. Mendoza, J. Mass, G. Kushner, and R.G. Miller Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis Neurology 62 2004 1845 1847
40. P.H. Gordon, C. Doorish, J. Montes, R.L. Mosley, B. Diamond, R.B. Macarthur, L.H. Weimer, P. Kaufmann, A.P. Hays, and L.P. Rowland Randomized controlled phase II trial of glatiramer acetate in ALS Neurology 66 2006 1117 1119
41. M.P. Gosland, B.L. Lum, and B.I. Sikic Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells Cancer Res. 49 1989 6901 6905
42. M. Graf, D. Ecker, R. Horowski, B. Kramer, P. Riederer, M. Gerlach, C. Hager, A.C. Ludolph, G. Becker, and J. Osterhage High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study J. Neural Transm. 112 2005 649 660
43. G.J. Groeneveld, F.L. van Muiswinkel, J. de Leeuw van Weenen, H. Blauw, J.H. Veldink, J.H. Wokke, L.H. van den Berg, and P.R. Bar CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5 2004 220 225
44. M.E. Gurney, F.B. Cutting, P. Zhai, A. Doble, C.P. Taylor, P.K. Andrus, and E.D. Hall Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis Ann. Neurol. 39 1996 147 157
45. M.E. Gurney, T.J. Fleck, C.S. Himes, and E.D. Hall Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis Neurology 50 1998 62 66
46. C. Haenggeli, J.P. Julien, R.L. Mosley, N. Perez, A. Dhar, H.E. Gendelman, and J.D. Rothstein Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS Neurobiol. Dis. 26 2007 146 152
47. A.M.S. Hartz, and B. Bauer ABC transporters in the CNS - an inventory Curr. Pharm. Biotechnol. 12 2011 656 673
48. A.M.S. Hartz, B. Bauer, G. Fricker, and D.S. Miller Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1 Mol. Pharmacol. 66 2004 387 394 10.1124/mol.104.001503.bition
49. A.M.S. Hartz, B. Bauer, A. Pekcec, K. Toellner, and D.S. Miller Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide Mol. Pharmacol. 69 2006 462 470 10.1124/mol.105.017954.pumps
50. A.M.S. Hartz, D.S. Miller, and B. Bauer Restoring blood-brain barrier P-glycoprotein reduces brain Aβ in a mouse model of Alzheimers disease Mol. Pharmacol. 77 2010 715 735 10.1124/mol.109.061754
51. M.T. Hoque, K.R. Robillard, and R. Bendayan Regulation of breast cancer resistant protein by peroxisome proliferator-activated receptor α in human brain microvessel endothelial cells Mol. Pharmacol. 81 2012 598 609 10.1124/mol.111.076745
52. K. Ikeda, B. Klinkosz, T. Greene, J.M. Cedarbaum, V. Wong, R.M. Lindsay, and H. Mitsumoto Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease Ann. Neurol. 37 1995 505 511
53. H. Ito, R. Wate, J. Zhang, S. Ohnishi, S. Kaneko, H. Ito, S. Nakano, and H. Kusaka Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice Exp. Neurol. 213 2008 448 455
54. M.R. Jablonski, D.A. Jacob, C.R. Campos, D.S. Miller, N.J. Maragakis, P. Pasinelli, and D. Trotti Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS Neurobiol. Dis. 47 2012 194 200 10.1016/j.nbd.2012.03.040
55. J.O. Johnson, J. Mandrioli, M. Benatar, Y. Abramzon, V.M. Van Deerlin, J.Q. Trojanowski, J.R. Gibbs, M. Brunetti, S. Gronka, J. Wuu, J. Ding, L.F. McCluskey, M. Martinez-Lage, D. Falcone, D.G. Hernandez, S. Arepalli, S. Chong, J.C. Schymick, J.D. Rothstein, F. Landi, Y.-D. Wang, A. Calvo, G. Mora, M. Sabatelli, M.R. Monsurrò, S. Battistini, F. Salvi, R. Spataro, P. Sola, G. Borghero, G. Galassi, S.W. Scholz, J.P. Taylor, G. Restagno, A. Chiò, and B.J. Traynor Exome sequencing reveals VCP mutations as a cause of familial ALS Neuron 68 2010 857 864 10.1016/j.neuron.2010.11.036
56. I.S. Joo, D.H. Hwang, J.I. Seok, S.K. Shin, and S.U. Kim Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis J. Clin. Neurol. 3 2007 181 186
57. K. Kadoyama, H. Funakoshi, W. Ohya, and T. Nakamura Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS Neurosci. Res. 59 2007 446 456
58. B. Kalmar, S. Novoselov, A. Gray, M.E. Cheetham, B. Margulis, and L. Greensmith Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS J. Neurochem. 107 2008 339 350
59. M. Kiaei, K. Kipiani, S. Petri, J. Chen, N.Y. Calingasan, and M.F. Beal Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis Neurodegener. Dis. 2 2005 246 254
60. M. Kiaei, S. Petri, K. Kipiani, G. Gardian, D.K. Choi, J. Chen, N.Y. Calingasan, P. Schafer, G.W. Muller, and C. Stewart Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis J. Neurosci. 26 2006 2467 2473
61. D. Kieran, B. Kalmar, J.R. Dick, J. Riddoch-Contreras, G. Burnstock, and L. Greensmith Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice Nat. Med. 10 2004 402 405
62. E. Kilic, A. Spudich, U. Kilic, K.M. Rentsch, R. Vig, C.M. Matter, H. Wunderli-Allenspach, J.-M. Fritschy, C.L. Bassetti, and D.M. Hermann ABCC1: a gateway for pharmacological compounds to the ischaemic brain Brain 131 2008 2679 2689 10.1093/brain/awn222
63. I.G. Kirkinezos, D. Hernandez, W.G. Bradley, and C.T. Moraes An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment J. Neurochem. 88 2004 821 826 10.1046/j.1471-4159.2003.02181.x
64. S. Knippenberg, N. Thau, R. Dengler, and S. Petri Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS) Behav. Brain Res. 213 2010 82 87 10.1016/j.bbr.2010.04.042
65. S.H. Koh, Y. Kim, H.Y. Kim, G.W. Cho, K.S. Kim, and S.H. Kim Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation Eur. J. Neurosci. 25 2007 1923 1930
66. Q. Kong, S. Carothers, Y. Chang, and C.-L. Glenn Lin The importance of preclinical trial timing - a potential reason for the disconnect between mouse studies and human clinical trials in ALS CNS Neurosci. Ther. 18 2012 791 793 10.1111/j.1755-5949.2012.00358.x
67. J. Kriz, M.D. Nguyen, and J.P. Julien Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis Neurobiol. Dis. 10 2002 268 278
68. T.J. Kwiatkowski, D.A. Bosco, A.L. Leclerc, E. Tamrazian, C.R. Vanderburg, C. Russ, A. Davis, J. Gilchrist, E.J. Kasarskis, T. Munsat, P. Valdmanis, G.A. Rouleau, B.A. Hosler, P. Cortelli, P.J. de Jong, Y. Yoshinaga, J.L. Haines, M.A. Pericak-Vance, J. Yan, N. Ticozzi, T. Siddique, D. McKenna-Yasek, P.C. Sapp, H.R. Horvitz, J.E. Landers, and R.J. Brown Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis Science 323 80 2009 1205 1208 10.1126/science.1166066
69. E.C. Lai, K.J. Felice, B.W. Festoff, M.J. Gawel, D.F. Gelinas, R. Kratz, M.F. Murphy, H.M. Natter, F.H. Norris, and S.A. Rudnicki Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group Neurology 49 1997 1621 1630
70. S.C. Landis, S.G. Amara, K. Asadullah, C.P. Austin, R. Blumenstein, E.W. Bradley, R.G. Crystal, R.B. Darnell, R.J. Ferrante, H. Fillit, R. Finkelstein, M. Fisher, H.E. Gendelman, R.M. Golub, J.L. Goudreau, R.A. Gross, A.K. Gubitz, S.E. Hesterlee, D.W. Howells, J. Huguenard, K. Kelner, W. Koroshetz, D. Krainc, S.E. Lazic, M.S. Levine, M.R. Macleod, J.M. McCall, R.T. Moxley, K. Narasimhan, L.J. Noble, S. Perrin, J.D. Porter, O. Steward, E. Unger, U. Utz, and S.D. Silberberg A call for transparent reporting to optimize the predictive value of preclinical research Nature 490 2012 187 191 10.1038/nature11556
71. D. Langford, A. Grigorian, R. Hurford, A. Adame, R.J. Ellis, L. Hansen, and E. Masliah Altered P-glycoprotein expression in AIDS patients with HIV encephalitis J. Neuropathol. Exp. Neurol. 63 2004 1038 1047
72. G. Lauria, A. Campanella, G. Filippini, A. Martini, P. Penza, L. Maggi, C. Antozzi, C. Ciano, P. Beretta, and D. Caldiroli Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability Amyotroph. Lateral Scler. 10 2009 410 415
73. J. Lee, H. Ryu, and N.W. Kowall Motor neuronal protection by L-arginine prolongs survival of mutant SOD1 (G93A) ALS mice Biochem. Biophys. Res. Commun. 384 2009 524 529
74. J. Lemmen, I.E.P. Tozakidis, and H.-J. Galla Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier Brain Res. 1491 2013 1 13 10.1016/j.brainres.2012.10.060
75. M. Li, V.O. Ona, C. Guegan, M. Chen, V. Jackson-Lewis, L.J. Andrews, A.J. Olszewski, P.E. Stieg, J.P. Lee, S. Przedborski, and R.M. Friedlander Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model Science 288 2000 335 339
76. S. Lorenzl, S. Narr, B. Angele, H.W. Krell, J. Gregorio, M. Kiaei, H.W. Pfister, and M.F. Beal The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice Exp. Neurol. 200 2006 166 171
77. W. Loscher, and H. Potschka Drug resistance in brain diseases and the role of drug efflux transporters Nat. Rev. Neurosci. 6 2005 591 602 10.1038/nrn1728
78. E.S. Louwerse, J.P. Buchet, M.A. Van Dijk, V.J. de Jong, and R.R. Lauwerys Urinary excretion of lead and mercury after oral administration of meso-2,3-dimercaptosuccinic acid in patients with motor neurone disease Int. Arch. Occup. Environ. Health 67 1995 135 138
79. A.C. Ludolph, C. Bendotti, E. Blaugrund, B. Hengerer, J.-P. Löffler, J. Martin, V. Meininger, T. Meyer, S. Moussaoui, W. Robberecht, S. Scott, V. Silani, and L.H. Van Den Berg Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop Amyotroph. Lateral Scler. 8 2007 217 223 10.1080/17482960701292837
80. N.J. Maragakis, M. Jackson, R. Ganel, and J.D. Rothstein Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice Neurosci. Lett. 338 2003 107 110
81. R.T. Matthews, L. Yang, S. Browne, M. Baik, and M.F. Beal Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects Proc. Natl. Acad. Sci. USA 95 1998 8892 8897
82. M.M. Maxwell, P. Pasinelli, A.G. Kazantsev, and R.J. Brown RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells Proc. Natl. Acad. Sci. USA 101 2004 3178 3183 10.1073/pnas.0308726100
83. V. Meininger, B. Asselain, P. Guillet, P.N. Leigh, A. Ludolph, L. Lacomblez, and W. Robberecht Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial Neurology 66 2006 88 92
84. V. Meininger, V.E. Drory, P.N. Leigh, A. Ludolph, W. Robberecht, and V. Silani Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial Amyotroph. Lateral Scler. 10 2009 378 383
85. A. Milane, C. Fernandez, S. Vautier, G. Bensimon, V. Meininger, and R. Farinotti Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier J. Neurochem. 103 2007 164 173 10.1111/j.1471-4159.2007.04772.x
86. A. Milane, S. Vautier, H. Chacun, V. Meininger, G. Bensimon, R. Farinotti, and C. Fernandez Interactions between riluzole and ABCG2/BCRP transporter Neurosci. Lett. 452 2009 12 16 10.1016/j.neulet.2008.12.061
87. A. Milane, C. Fernandez, L. Dupuis, M. Buyse, J. Loeffler, R. Farinotti, V. Meininger, and G. Bensimon Neuroscience letters P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis Neurosci. Lett. 472 2010 166 170 10.1016/j.neulet.2010.01.078
88. D.S. Miller Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier Trends Pharmacol. Sci. 31 2010 246 254 10.1016/j.tips.2010.03.003
89. H. Mitsumoto, K. Ikeda, B. Klinkosz, J.M. Cedarbaum, V. Wong, and R.M. Lindsay Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF Science 265 1994 1107 1110
90. M. Neumann, D.M. Sampathu, L.K. Kwong, A.C. Truax, M.C. Micsenyi, T.T. Chou, J. Bruce, T. Schuck, M. Grossman, C.M. Clark, L.F. McCluskey, B.L. Miller, E. Masliah, I.R. Mackenzie, H. Feldman, W. Feiden, H.A. Kretzschmar, J.Q. Trojanowski, and V.M.-Y. Lee Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis Science 314 80 2006 130 133 10.1126/science.1134108
91. E.A. Neuwelt, B. Bauer, C. Fahlke, G. Fricker, C. Iadecola, D. Janigro, L. Leybaert, Z. Molnár, M.E. O'Donnell, J.T. Povlishock, N.R. Saunders, F. Sharp, D. Stanimirovic, R.J. Watts, and L.R. Drewes Engaging neuroscience to advance translational research in brain barrier biology Nat. Rev. Neurosci. 12 2011 169 182 10.1038/nrn2995
92. A. Nies, G. Jedlitschky, J. König, C. Herold-Mende, H.H. Steiner, H.-P. Schmitt, and D. Keppler Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain Neuroscience 129 2004 349 360 10.1016/j.neuroscience.2004.07.051
93. M. Paizs, M. Tortarolo, C. Bendotti, J.I. Engelhardt, and L. Siklos Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically Amyotroph. Lateral Scler. 12 2011 340 344
94. W.M. Pardridge, P.L. Golden, Y.S. Kang, and U. Bickel Brain microvascular and astrocyte localization of P-glycoprotein J. Neurochem. 68 1997 1278 1285
95. R.M. Pascuzzi, J. Shefner, A.S. Chappell, J.S. Bjerke, R. Tamura, V. Chaudhry, L. Clawson, L. Haas, and J.D. Rothstein A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis Amyotroph. Lateral Scler. 11 2010 266 271
96. G.L. Pattee, G.R. Post, R.E. Gerber, and J.P. Bennett Jr. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4 2003 90 95
97. S. Piepers, J.H. Veldink, S.W. de Jong, I. van der Tweel, W.L. van der Pol, E.V. Uijtendaal, H.J. Schelhaas, H. Scheffer, M. de Visser, and J.M. de Jong Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis Ann. Neurol. 66 2009 227 234
98. C. Pitzer, C. Kruger, C. Plaas, F. Kirsch, T. Dittgen, R. Muller, R. Laage, S. Kastner, S. Suess, and R. Spoelgen Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis Brain: J. Neurol. 131 2008 3335 3347
99. H. Potschka Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport Adv. Drug Deliv. Rev. 64 2012 943 952 10.1016/j.addr.2011.12.007
100. A.E. Renton, E. Majounie, A.J. Waite, J. Simón-Sánchez, S. Rollinson, J.R. Gibbs, J.C. Schymick, H. Laaksovirta, J.C. van Swieten, L. Myllykangas, H. Kalimo, A. Paetau, Y. Abramzon, A.M. Remes, A. Kaganovich, S.W. Scholz, J. Duckworth, J. Ding, D.W. Harmer, D.G. Hernandez, J.O. Johnson, K. Mok, M. Ryten, D. Trabzuni, R.J. Guerreiro, R.W. Orrell, J.W. Neal, A. Murray, J. Pearson, I.E. Jansen, D. Sondervan, H. Seelaar, D.J. Blake, K. Young, N. Halliwell, J.B. Callister, G. Toulson, A. Richardson, A. Gerhard, J. Snowden, D. Mann, D. Neary, M.A. Nalls, T. Peuralinna, L. Jansson, V.-M. Isoviita, A.-L. Kaivorinne, M. Hölttä-Vuori, E. Ikonen, R. Sulkava, M. Benatar, J. Wuu, A. Chiò, G. Restagno, G. Borghero, M. Sabatelli, D. Heckerman, E. Rogaeva, L. Zinman, J.D. Rothstein, M. Sendtner, C. Drepper, E.E. Eichler, C. Alkan, Z. Abdullaev, S.D. Pack, A. Dutra, E. Pak, J. Hardy, A. Singleton, N.M. Williams, P. Heutink, S. Pickering-Brown, H.R. Morris, P.J. Tienari, and B.J. Traynor A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD Neuron 72 2011 257 268 10.1016/j.neuron.2011.09.010
101. J. Riddoch-Contreras, S.Y. Yang, J.R. Dick, G. Goldspink, R.W. Orrell, and L. Greensmith Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice Exp. Neurol. 215 2009 281 289
102. D. Rosen, T. Siddique, D. Patterson, D. Figlewicz, P.C. Sapp, and A. Hentati Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis Nature 362 1993 59 62
103. J.D. Rothstein, S. Patel, M.R. Regan, C. Haenggeli, Y.H. Huang, D.E. Bergles, L. Jin, M. Dykes Hoberg, S. Vidensky, and D.S. Chung Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression Nature 433 2005 73 77
104. C. Rouaux, I. Panteleeva, F. Rene, J.L. Gonzalez de Aguilar, A. Echaniz-Laguna, L. Dupuis, Y. Menger, A.L. Boutillier, and J.P. Loeffler Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model J. Neurosci. 27 2007 5535 5545
105. H. Ryu, K. Smith, S.I. Camelo, I. Carreras, J. Lee, A.H. Iglesias, F. Dangond, K.A. Cormier, M.E. Cudkowicz, R.H. Brown Jr., and R.J. Ferrante Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice J. Neurochem. 93 2005 1087 1098
106. S. Saenger, B. Holtmann, M.R. Nilges, S. Schroeder, A. Hoeflich, H. Kletzl, W. Spooren, S. Ostrowitzki, T. Hanania, M. Sendtner, and F. Metzger Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity Amyotroph. Lateral Scler. 13 2012 418 429
107. Y. Sagot, N. Toni, D. Perrelet, S. Lurot, B. King, H. Rixner, L. Mattenberger, P.C. Waldmeier, and A.C. Kato An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease Br. J. Pharmacol. 131 2000 721 728
108. S.A. Sakowski, A.D. Schuyler, and E.L. Feldman Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis Amyotroph. Lateral Scler. 10 2009 63 73
109. B. Schutz, J. Reimann, L. Dumitrescu-Ozimek, K. Kappes-Horn, G.E. Landreth, B. Schurmann, A. Zimmer, and M.T. Heneka The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice J. Neurosci. 25 2005 7805 7812
110. B.C. Shaffer, J.-P. Gillet, C. Patel, M.R. Baer, S.E. Bates, and M.M. Gottesman Drug resistance: still a daunting challenge to the successful treatment of AML Drug Discov. Today 15 2012 62 69 10.1016/j.drup.2012.02.001
111. J.M. Shefner, M.E. Cudkowicz, D. Schoenfeld, T. Conrad, J. Taft, M. Chilton, L. Urbinelli, M. Qureshi, H. Zhang, and A. Pestronk A clinical trial of creatine in ALS Neurology 63 2004 1656 1661
112. J.L. Shoemaker, K.A. Seely, R.L. Reed, J.P. Crow, and P.L. Prather The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset J. Neurochem. 101 2007 87 98
113. T. Siddique, and S. Ajroud-Driss Familial amyotrophic lateral sclerosis, a historical perspective Acta Myol. 30 2011 117 120
114. A. Soontornmalai, M.L.H. Vlaming, and J.-M. Fritschy Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier Neuroscience 138 2006 159 169 10.1016/j.neuroscience.2005.11.011
115. E.W. Stommel, J.A. Cohen, C.E. Fadul, C.H. Cogbill, D.J. Graber, L. Kingman, T. Mackenzie, J.Y. Channon Smith, and B.T. Harris Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial Amyotroph. Lateral Scler. 10 2009 393 404
116. F. Sugai, Y. Yamamoto, K. Miyaguchi, Z. Zhou, H. Sumi, T. Hamasaki, M. Goto, and S. Sakoda Benefit of valproic acid in suppressing disease progression of ALS model mice Eur. J. Neurosci. 20 2004 3179 3183
117. W. Sun, H. Funakoshi, and T. Nakamura Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS J. Neurosci. 22 2002 6537 6548
118. M. Suzuki, J. McHugh, C. Tork, B. Shelley, A. Hayes, I. Bellantuono, P. Aebischer, and C.N. Svendsen Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS Mol. Ther. 16 2008 2002 2010
119. D. Theron, S.B. de Lagerie, S. Tardivel, H. Pelerin, P. Demeuse, C. Mercier, A. Mabondzo, R. Farinotti, B. Lacour, F. Roux, and F. Gimenez Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line Biochem. Pharmacol. 66 2003 579 587
120. E. Tokuda, S. Ono, K. Ishige, S. Watanabe, E. Okawa, Y. Ito, and T. Suzuki Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis Exp. Neurol. 213 2008 122 128
121. Y.R.L.B. Tovar, A. Zepeda, and R. Tapia Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration J. Neuropathol. Exp. Neurol. 66 2007 913 922
122. B.J. Turner, and K. Talbot Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS Prog. Neurobiol. 85 2008 94 134 10.1016/j.pneurobio.2008.01.001
123. D.M.E. Van Assema, M. Lubberink, M. Bauer, W.M. van der Flier, R.C. Schuit, A.D. Windhorst, E.F.I. Comans, N.J. Hoetjes, N. Tolboom, O. Langer, M. Müller, P. Scheltens, A.A. Lammertsma, and B.N.M. van Berckel Blood-brain barrier P-glycoprotein function in Alzheimers disease Brain 135 2012 181 189 10.1093/brain/awr298
124. D.M.E. Van Assema, M. Lubberink, R. Boellaard, R.C. Schuit, A.D. Windhorst, P. Scheltens, A.A. Lammertsma, and B.N.M. van Berckel P-glycoprotein function at the blood-brain barrier: effects of age and gender Mol. Imaging Biol. 14 2012 771 776 10.1007/s11307-012-0556-0
125. L. Van Den Bosch, P. Tilkin, G. Lemmens, and W. Robberecht Minocycline delays disease onset and mortality in a transgenic model of ALS Neuroreport 13 2002 1067 1070
126. C. Vance, B. Rogelj, T. Hortobagyi, and C.E. Shaw Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6 Science 323 80 2009 1208 1211
127. S. Waibel, A. Reuter, S. Malessa, E. Blaugrund, and A.C. Ludolph Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model J. Neurol. 251 2004 1080 1084
128. R. Wang, and D. Zhang Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model Eur. J. Neurosci. 22 2005 2376 2380
129. H. Wang, K.S. Larriviere, K.E. Keller, K.A. Ware, T.M. Burns, M.A. Conaway, D. Lacomis, G.L. Pattee, L.H. Phillips 2nd, and N.J. Solenski R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS Amyotroph. Lateral Scler. 9 2008 50 58
130. M. Westerlund, A.C. Belin, L. Olson, and D. Galter Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients Cell Tissue Res. 334 2008 179 185 10.1007/s00441-008-0686-5
131. H. Xiong, D. Callaghan, A. Jones, J. Bai, I. Rasquinha, C. Smith, K. Pei, D. Walker, L.-F. Lue, D. Stanimirovic, and W. Zhang ABCG2 is upregulated in Alzheimers brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides J. Neurosci. 29 2009 5463 5475 10.1523/JNEUROSCI.5103-08.2009
132. N. Yu, Q. Di, H. Liu, Y. Hu, Y. Jiang, Y. Yan, Y. Zhang, and Y. Zhang Nuclear factor-kappa B activity regulates brain expression of P-glycoprotein in the kainic acid-induced seizure rats Mediat. Inflamm. 2011 2011 670613 10.1155/2011/670613
133. W. Zhang, M. Narayanan, and R.M. Friedlander Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS Ann. Neurol. 53 2003 267 270 10.1002/ana.10476
134. Y. Zhang, J.D. Schuetz, W.F. Elmquist, and D.W. Miller Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells J. Pharmacol. Exp. Ther. 311 2004 449 455 10.1124/jpet.104.068528.pathological
135. X. Zhang, S. Chen, L. Li, Q. Wang, and W. Le Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice Neuropharmacology 54 2008 1112 1119
136. C. Zheng, M.K. Skold, J. Li, I. Nennesmo, B. Fadeel, and J.I. Henter VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice Biochem. Biophys. Res. Commun. 363 2007 989 993
137. S. Zhu, I.G. Stavrovskaya, M. Drozda, B.Y. Kim, V. Ona, M. Li, S. Sarang, A.S. Liu, D.M. Hartley, and D.C. Wu Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice Nature 417 2002 74 78